To find the key CD8+ TIL subgroup in HNSCC immune microenvironment, we first evaluated the frequency of different subsets of PD-1+ TILs, which is the basis of PD-1/PD-L1 immunotherapy26,27 (Fig. 2a). This evidence concerns the gene CD274 and head and neck squamous cell carcinoma.